The ratio of CD8 to Treg tumor-infiltrating lymphocytes is associated with response to cisplatin-based neoadjuvant chemotherapy in patients with muscle invasive urothelial carcinoma of the bladder

Alexander S. Baras, Charles Drake, Jen Jane Liu, Nilay Gandhi, Max Kates, Mohamed O. Hoque, Alan Meeker, Noah Hahn, Janis M. Taube, Mark P. Schoenberg, George Netto, Trinity J. Bivalacqua

Research output: Contribution to journalArticle

49 Citations (Scopus)

Abstract

Introduction: Randomized controlled trials of platinum-based neoadjuvant chemotherapy (NAC) for bladder cancer have shown that patients who achieve a pathologic response to NAC exhibit 5 y survival rates of approximately 80–90% while NAC resistant (NR) cases exhibit 5 y survival rates of approximately 30–40%. These findings highlight the need to predict who will benefit from conventional NAC and the need for plausible alternatives. Methods: The pre-treatment biopsy tissues from a cohort of 41 patients with muscle invasive bladder who were treated with NAC were incorporated in tissue microarray and immunohistochemistry for PD-L1, CD8, and FOXP3 was performed. Percentage of PD-L1 positive tumor cells was measured. Tumor-infiltrating lymphocytes (TIL) densities, along with CD8 and Treg-specific TILs, were measured. Results: TIL density was strongly correlated with tumor PD-L1 expression, consistent with the mechanism of adaptive immune resistance in bladder cancer. Tumor cell PD-L1 expression was not a significant predictor of response. Neither was the CD8 nor Treg TIL density associated with response. Intriguingly though, the ratio of CD8 to Treg TIL densities was strongly associated with response (p = 0.0003), supporting the hypothesis that the immune system plays a role in the response of bladder cancer to chemotherapy. Discussion: To our knowledge, this is the first report in bladder cancer showing that the CD8 to Treg TIL density in the pre-treatment tissues is predictive for conventional NAC response. These findings warrant further investigations to both better characterize this association in larger cohorts and begin to elucidate the underlying mechanism(s) of this phenomenon.

Original languageEnglish (US)
Article numbere1134412
JournalOncoImmunology
Volume5
Issue number5
DOIs
StatePublished - May 3 2016

Fingerprint

Tumor-Infiltrating Lymphocytes
Cisplatin
Urinary Bladder
Carcinoma
Drug Therapy
Muscles
Urinary Bladder Neoplasms
Survival Rate
Neoplasms
Platinum
Immune System
Randomized Controlled Trials
Immunohistochemistry
Biopsy
Therapeutics

Keywords

  • Biomarkers
  • Bladder cancer
  • Chemotherapy
  • Immunology
  • Neoadjuvant

ASJC Scopus subject areas

  • Immunology and Allergy
  • Oncology
  • Immunology

Cite this

The ratio of CD8 to Treg tumor-infiltrating lymphocytes is associated with response to cisplatin-based neoadjuvant chemotherapy in patients with muscle invasive urothelial carcinoma of the bladder. / Baras, Alexander S.; Drake, Charles; Liu, Jen Jane; Gandhi, Nilay; Kates, Max; Hoque, Mohamed O.; Meeker, Alan; Hahn, Noah; Taube, Janis M.; Schoenberg, Mark P.; Netto, George; Bivalacqua, Trinity J.

In: OncoImmunology, Vol. 5, No. 5, e1134412, 03.05.2016.

Research output: Contribution to journalArticle

Baras, Alexander S. ; Drake, Charles ; Liu, Jen Jane ; Gandhi, Nilay ; Kates, Max ; Hoque, Mohamed O. ; Meeker, Alan ; Hahn, Noah ; Taube, Janis M. ; Schoenberg, Mark P. ; Netto, George ; Bivalacqua, Trinity J. / The ratio of CD8 to Treg tumor-infiltrating lymphocytes is associated with response to cisplatin-based neoadjuvant chemotherapy in patients with muscle invasive urothelial carcinoma of the bladder. In: OncoImmunology. 2016 ; Vol. 5, No. 5.
@article{649e2bcc5df143a7b49b7dd4e0c2537e,
title = "The ratio of CD8 to Treg tumor-infiltrating lymphocytes is associated with response to cisplatin-based neoadjuvant chemotherapy in patients with muscle invasive urothelial carcinoma of the bladder",
abstract = "Introduction: Randomized controlled trials of platinum-based neoadjuvant chemotherapy (NAC) for bladder cancer have shown that patients who achieve a pathologic response to NAC exhibit 5 y survival rates of approximately 80–90{\%} while NAC resistant (NR) cases exhibit 5 y survival rates of approximately 30–40{\%}. These findings highlight the need to predict who will benefit from conventional NAC and the need for plausible alternatives. Methods: The pre-treatment biopsy tissues from a cohort of 41 patients with muscle invasive bladder who were treated with NAC were incorporated in tissue microarray and immunohistochemistry for PD-L1, CD8, and FOXP3 was performed. Percentage of PD-L1 positive tumor cells was measured. Tumor-infiltrating lymphocytes (TIL) densities, along with CD8 and Treg-specific TILs, were measured. Results: TIL density was strongly correlated with tumor PD-L1 expression, consistent with the mechanism of adaptive immune resistance in bladder cancer. Tumor cell PD-L1 expression was not a significant predictor of response. Neither was the CD8 nor Treg TIL density associated with response. Intriguingly though, the ratio of CD8 to Treg TIL densities was strongly associated with response (p = 0.0003), supporting the hypothesis that the immune system plays a role in the response of bladder cancer to chemotherapy. Discussion: To our knowledge, this is the first report in bladder cancer showing that the CD8 to Treg TIL density in the pre-treatment tissues is predictive for conventional NAC response. These findings warrant further investigations to both better characterize this association in larger cohorts and begin to elucidate the underlying mechanism(s) of this phenomenon.",
keywords = "Biomarkers, Bladder cancer, Chemotherapy, Immunology, Neoadjuvant",
author = "Baras, {Alexander S.} and Charles Drake and Liu, {Jen Jane} and Nilay Gandhi and Max Kates and Hoque, {Mohamed O.} and Alan Meeker and Noah Hahn and Taube, {Janis M.} and Schoenberg, {Mark P.} and George Netto and Bivalacqua, {Trinity J.}",
year = "2016",
month = "5",
day = "3",
doi = "10.1080/2162402X.2015.1134412",
language = "English (US)",
volume = "5",
journal = "OncoImmunology",
issn = "2162-4011",
publisher = "Landes Bioscience",
number = "5",

}

TY - JOUR

T1 - The ratio of CD8 to Treg tumor-infiltrating lymphocytes is associated with response to cisplatin-based neoadjuvant chemotherapy in patients with muscle invasive urothelial carcinoma of the bladder

AU - Baras, Alexander S.

AU - Drake, Charles

AU - Liu, Jen Jane

AU - Gandhi, Nilay

AU - Kates, Max

AU - Hoque, Mohamed O.

AU - Meeker, Alan

AU - Hahn, Noah

AU - Taube, Janis M.

AU - Schoenberg, Mark P.

AU - Netto, George

AU - Bivalacqua, Trinity J.

PY - 2016/5/3

Y1 - 2016/5/3

N2 - Introduction: Randomized controlled trials of platinum-based neoadjuvant chemotherapy (NAC) for bladder cancer have shown that patients who achieve a pathologic response to NAC exhibit 5 y survival rates of approximately 80–90% while NAC resistant (NR) cases exhibit 5 y survival rates of approximately 30–40%. These findings highlight the need to predict who will benefit from conventional NAC and the need for plausible alternatives. Methods: The pre-treatment biopsy tissues from a cohort of 41 patients with muscle invasive bladder who were treated with NAC were incorporated in tissue microarray and immunohistochemistry for PD-L1, CD8, and FOXP3 was performed. Percentage of PD-L1 positive tumor cells was measured. Tumor-infiltrating lymphocytes (TIL) densities, along with CD8 and Treg-specific TILs, were measured. Results: TIL density was strongly correlated with tumor PD-L1 expression, consistent with the mechanism of adaptive immune resistance in bladder cancer. Tumor cell PD-L1 expression was not a significant predictor of response. Neither was the CD8 nor Treg TIL density associated with response. Intriguingly though, the ratio of CD8 to Treg TIL densities was strongly associated with response (p = 0.0003), supporting the hypothesis that the immune system plays a role in the response of bladder cancer to chemotherapy. Discussion: To our knowledge, this is the first report in bladder cancer showing that the CD8 to Treg TIL density in the pre-treatment tissues is predictive for conventional NAC response. These findings warrant further investigations to both better characterize this association in larger cohorts and begin to elucidate the underlying mechanism(s) of this phenomenon.

AB - Introduction: Randomized controlled trials of platinum-based neoadjuvant chemotherapy (NAC) for bladder cancer have shown that patients who achieve a pathologic response to NAC exhibit 5 y survival rates of approximately 80–90% while NAC resistant (NR) cases exhibit 5 y survival rates of approximately 30–40%. These findings highlight the need to predict who will benefit from conventional NAC and the need for plausible alternatives. Methods: The pre-treatment biopsy tissues from a cohort of 41 patients with muscle invasive bladder who were treated with NAC were incorporated in tissue microarray and immunohistochemistry for PD-L1, CD8, and FOXP3 was performed. Percentage of PD-L1 positive tumor cells was measured. Tumor-infiltrating lymphocytes (TIL) densities, along with CD8 and Treg-specific TILs, were measured. Results: TIL density was strongly correlated with tumor PD-L1 expression, consistent with the mechanism of adaptive immune resistance in bladder cancer. Tumor cell PD-L1 expression was not a significant predictor of response. Neither was the CD8 nor Treg TIL density associated with response. Intriguingly though, the ratio of CD8 to Treg TIL densities was strongly associated with response (p = 0.0003), supporting the hypothesis that the immune system plays a role in the response of bladder cancer to chemotherapy. Discussion: To our knowledge, this is the first report in bladder cancer showing that the CD8 to Treg TIL density in the pre-treatment tissues is predictive for conventional NAC response. These findings warrant further investigations to both better characterize this association in larger cohorts and begin to elucidate the underlying mechanism(s) of this phenomenon.

KW - Biomarkers

KW - Bladder cancer

KW - Chemotherapy

KW - Immunology

KW - Neoadjuvant

UR - http://www.scopus.com/inward/record.url?scp=84975795348&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84975795348&partnerID=8YFLogxK

U2 - 10.1080/2162402X.2015.1134412

DO - 10.1080/2162402X.2015.1134412

M3 - Article

AN - SCOPUS:84975795348

VL - 5

JO - OncoImmunology

JF - OncoImmunology

SN - 2162-4011

IS - 5

M1 - e1134412

ER -